A randomized controlled trial of Endoscopic surVEillance with NBI or iodine staining for patients after Endoscopic RESecTion of esophageal squamous cell carcinoma

未提供0 个研究点目标入组 1,700 人开始时间: 2024年11月8日最近更新: 2025年4月14日

试验速览

暂无简介。

•(1) Upper gastrointestinal endoscopy for surveillance after endoscopic resection of histopathologically diagnosed primary esophageal squamous cell carcinoma (ESCC) is planned.
•(2) Histopathology of all endoscopic resections was pT1a, negative for lymphovascular invasion, and negative for vertical margin.
•(3) The previous upper gastrointestinal endoscopy with iodine staining of the entire esophagus was performed within 6 months, and all histopathologically diagnosed ESCCs were endoscopically resected.
•(4) Additional treatment is not planned after endoscopic resection of ESCC.
•(5) No previous treatment for ESCC other than endoscopic resection.
•(6) No previous radiation therapy for the chest, lung field, or mediastinum for any cancer types.
•(7) No previous surgery for the esophagus or mediastinum including for benign tumors.
•(8) No pharyngeal or esophageal stricture where the standard endoscope cannot pass.
•(9) Age between 18 and 80 years.
•(10) An Eastern Cooperative Oncology Group Performance Status of 0 or
•(11) Endoscopic surveillance for 3 years after registration is considered feasible.
•(12) Provision of written informed consent for participation in the trial.

•(1) Other primary cancers within the previous 5 years except intramucosal tumors cured with local therapy.
•(2) A history of iodine allergy.
•(3) Severe mental disease.
•(4) The investigator considered ineligible as subjects.

Targeted ESCC-free survival

未报告次要终点

发起方

未提供